Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

P. Bramanti; E. Sessa; C. Rifici; G. D'Aleo; D. Floridia; P. Di Bella; F. Lublin

doi:10.1212/WNL.51.6.1720

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

P. Bramanti, E. Sessa, C. Rifici, G. D'Aleo, D. Floridia, P. Di Bella, F. Lublin

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

Original language	English
Pages (from-to)	1720-1723
Number of pages	4
Journal	Neurology
Volume	51
Issue number	6
DOIs	https://doi.org/10.1212/WNL.51.6.1720
State	Published - Dec 1998
Externally published	Yes

Access to Document

10.1212/WNL.51.6.1720

Cite this

@article{7d0857e98f8746acae6431366ebd9c95,

title = "Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b",

abstract = "Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.",

author = "P. Bramanti and E. Sessa and C. Rifici and G. D'Aleo and D. Floridia and {Di Bella}, P. and F. Lublin",

year = "1998",

month = dec,

doi = "10.1212/WNL.51.6.1720",

language = "English",

volume = "51",

pages = "1720--1723",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

AU - Bramanti, P.

AU - Sessa, E.

AU - Rifici, C.

AU - D'Aleo, G.

AU - Floridia, D.

AU - Di Bella, P.

AU - Lublin, F.

PY - 1998/12

Y1 - 1998/12

N2 - Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

AB - Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFNβ-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNβ-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

UR - http://www.scopus.com/inward/record.url?scp=0031676732&partnerID=8YFLogxK

U2 - 10.1212/WNL.51.6.1720

DO - 10.1212/WNL.51.6.1720

M3 - Article

C2 - 9855531

AN - SCOPUS:0031676732

SN - 0028-3878

VL - 51

SP - 1720

EP - 1723

JO - Neurology

JF - Neurology

IS - 6

ER -

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

Abstract

Access to Document

Fingerprint

Cite this